Roivant creates Pulmovant to house lung disorder drug licensed from Bayer

seekingalpha09-10

Roivant (NASDAQ:ROIV) on Tuesday announced Pulmovant, the latest Vant member in its organizational structure, to house a lung disorder therapy called mosliciguat in licensed from German conglomerate ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2466439841?lang=en_US&edition=fundamental","thumbnail":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1358641817/image_1358641817.jpg","is_english":true,"pubTime":"2024-09-10 18:59","share_image_url":"https://static.laohu8.com/5a36db9d73b4222bc376d24ccc48c8a4","id":"2466439841","market":"us","top_or_hot":-1,"title":"Roivant creates Pulmovant to house lung disorder drug licensed from Bayer","media":"seekingalpha","content":"<div>\n<p>Roivant (NASDAQ:ROIV) on Tuesday announced Pulmovant, the latest Vant member in its organizational structure, to house a lung disorder therapy called mosliciguat in licensed from German conglomerate ...</p>\n\n<a href=\"https://seekingalpha.com/news/4148267-roivant-forms-pulmovant-house-bayer-owned-drug\">Source Link</a>\n\n</div>\n","source":"seekingalpha","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Roivant creates Pulmovant to house lung disorder drug licensed from Bayer</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nRoivant creates Pulmovant to house lung disorder drug licensed from Bayer\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-09-10 18:59 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/news/4148267-roivant-forms-pulmovant-house-bayer-owned-drug><strong>seekingalpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Roivant (NASDAQ:ROIV) on Tuesday announced Pulmovant, the latest Vant member in its organizational structure, to house a lung disorder therapy called mosliciguat in licensed from German conglomerate ...</p>\n\n<a href=\"https://seekingalpha.com/news/4148267-roivant-forms-pulmovant-house-bayer-owned-drug\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"ROIV","symbol_name":"Roivant Sciences Ltd.","start_time":0,"source_url":"https://seekingalpha.com/news/4148267-roivant-forms-pulmovant-house-bayer-owned-drug","article_id":"2466439841","we_media_id":null,"thumbnails":["https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1358641817/image_1358641817.jpg"],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2466439841","pubTimestamp":1725965990,"sourceInfo":{"source_id":"seekingalpha","name":"Seeking Alpha"},"weMediaInfo":null,"summary":"Roivant  on Tuesday announced Pulmovant, the latest Vant member in its organizational structure, to house a lung disorder therapy called mosliciguat in licensed from German conglomerate Bayer  . U.K.-based Roivant  advances its pipeline through a Vant structure designed to develop and commercialize its medicines and technologies. The company said Pulmovant will be created to hold the exclusive worldwide rights linked to mosliciguat, a once-daily inhaled therapy targeted for lung delivery via dry powder inhaler. As part of the licensing deal, Bayer  has received $14.0M in upfront cash with up to $280M pledged in the form of milestone payments in addition to tiered high-single-digit sales-based royalties. Shortly, Pulmovant is set to start enrollments for a global Phase 2 trial called PHocus to assess mosliciguat in about 120 patients with pulmonary hypertension associated with interstitial lung disease . Affecting about 200K patients in the U.S. and Europe with limited or no treatment o","collect":0,"end_time":0,"defaultTopTitle":"seekingalpha.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"ROIV":"Roivant Sciences Ltd.","BAYZF":"Bayer A.G.","BK4139":"生物科技","BK4007":"制药","BAYRY":"Bayer A.G."},"translate_title":"Roivant创建Pulmovant以容纳拜耳许可的肺部疾病药物","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"BAYRY":1,"BAYZF":1,"ROIV":1},"content_text":"Roivant (NASDAQ:ROIV) on Tuesday announced Pulmovant, the latest Vant member in its organizational structure, to house a lung disorder therapy called mosliciguat in licensed from German conglomerate Bayer (OTCPK:BAYZF) (OTCPK:BAYRY). U.K.-based Roivant (ROIV) advances its pipeline through a Vant structure designed to develop and commercialize its medicines and technologies. The company said Pulmovant will be created to hold the exclusive worldwide rights linked to mosliciguat, a once-daily inhaled therapy targeted for lung delivery via dry powder inhaler. As part of the licensing deal, Bayer (OTCPK:BAYZF) has received $14.0M in upfront cash with up to $280M pledged in the form of milestone payments in addition to tiered high-single-digit sales-based royalties. Shortly, Pulmovant is set to start enrollments for a global Phase 2 trial called PHocus to assess mosliciguat in about 120 patients with pulmonary hypertension associated with interstitial lung disease (PH-ILD). Affecting about 200K patients in the U.S. and Europe with limited or no treatment options, PH-ILD represents a larger commercial opportunity for Roivant (ROIV) compared to another lung disorder called pulmonary arterial hypertension (PAH).","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.28.1","shortVersion":"4.28.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2466439841"}